Diagnostic Evaluation of Hypertrophic Cardiomyopathy in its Clinical and Preclinical Phases

Beatriz Piva e Mattos, Marco Antonio Rodrigues Torres, Valéria Centeno de Freitas
Serviço de Cardiologia do Hospital de Clínicas de Porto Alegre, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brazil

Abstract

Hypertrophic cardiomyopathy is a familial, genetic disease caused by mutations in genes encoding sarcomeric proteins. It is characterized by various degrees of left ventricular hypertrophy, usually diffuse, predominantly involving the interventricular septum. The asymptomatic forms with mild or no segmental hypertrophy make it difficult to establish the diagnosis and screening for familial forms. Its high penetrance is often incomplete and, as a result, 20% to 30% of adults who carry disease-causing gene mutations do not express the phenotype. The susceptibility to sudden death and likelihood of late expression makes establishing a preclinical diagnosis all the more important.

The use of Doppler echocardiography and magnetic resonance imaging, in conjunction with a detailed ECG analysis, may be useful in this process. Molecular genetic studies can identify mutations in 60% to 80% of the cases. However, its complex, time-consuming and costly nature, coupled with an inadequate assessment of genotype-phenotype relationships, limits its routine application. Major advances in imaging methods and the introduction of more simplified molecular techniques may contribute to clinical and preclinical diagnosis of hypertrophic cardiomyopathy, in addition to allowing implementation of therapeutic strategies to prevent or delay the development of the disease.

Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy (LVH) in the absence of chamber dilation and any other cardiovascular or systemic condition capable of producing similar changes. The presence of cellular disarray, fibrosis, and myocyte hypertrophy contributes to the development of diastolic dysfunction, myocardial ischemia, and arrhythmias, which are the substrate of the disease’s clinical manifestations.

Since it was first described, more than four decades ago, HCM has been a subject of intense and fruitful investigation. It is the most prevalent genetic cardiovascular disease, affecting one in every 500 individuals. This is a familial disease with predominantly autosomal dominant pattern of inheritance.

More than 400 mutations in genes encoding sarcomeric proteins have already been identified (Table 1). Mutations in the β-myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3) genes seem to account for 60% to 80% of the cases.

The great molecular, pathological, and clinical heterogeneity of HCM complicates its diagnosis. Clinical diagnosis is based on predominantly asymmetric LVH associated with normal or reduced cavity on two-dimensional Doppler echocardiography or magnetic resonance imaging. Atypical forms with mild, localized or nondetectable LVH are usually challenging, making screening for affected individuals more difficult in families known to carry the disease.

Hypertrophic cardiomyopathy is the most common cause of sudden death in young people and athletes, including asymptomatic patients without prior diagnosis or signs of LVH. The susceptibility to devastating complications, such as sudden death, and progression to disabling conditions, such as heart failure, have prompted a search for indicators capable of identifying the disease at earlier stages. The advent of molecular genetic diagnosis has significantly contributed to the detection of gene mutation carriers without evidence of disease. Because of the incomplete phenotypic penetrance of HCM, Doppler echocardiography fails to detect LVH in 20% to 30% of the genetically affected adult patients.

These individuals may show premature predisposition to sudden death or develop the phenotype later in life, as it is the case with mutations in troponin T and cardiac myosin-

Table 1 - Sarcomeric genes known to cause hypertrophic cardiomyopathy

<table>
<thead>
<tr>
<th>Sarcomeric Genes Known to Cause Hypertrophic Cardiomyopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac β-myosin heavy chain (MYH7)</td>
</tr>
<tr>
<td>Myosin-binding protein C (MYBPC3)</td>
</tr>
<tr>
<td>Troponin T (TNN1)</td>
</tr>
<tr>
<td>α-tropomyosin (TPM1)</td>
</tr>
<tr>
<td>Essential myosin light chains (MYL3)</td>
</tr>
<tr>
<td>Regulatory myosin light chains (MYL2)</td>
</tr>
<tr>
<td>Troponin I (TNN3)</td>
</tr>
<tr>
<td>α-actin (ACTC)</td>
</tr>
<tr>
<td>Titin (TTN)</td>
</tr>
<tr>
<td>Troponin C (TNNC1)</td>
</tr>
<tr>
<td>α-myosin heavy chain (MYH6)</td>
</tr>
<tr>
<td>Muscle LIM protein (CRP3)</td>
</tr>
</tbody>
</table>
binding protein-C genes, respectively. Improvements in imaging methods for assessing left ventricular function and larger scale use of molecular genetic diagnosis may contribute substantially to the identification of the disease in its clinical and preclinical phases.

Clinical features

Hypertrophic cardiomyopathy affects both genders, occurring in patients of different racial backgrounds and in multiple geographic areas. It usually develops during adolescence, although its clinical manifestations may appear earlier or later, after the fifth decade of life. Typically, HCM occurs between the ages 13 and 17 in carriers of HCM-causing gene mutations. Morphological features are usually complete at the age of 18, and there is no progression of left ventricular hypertrophy after this age. The elderly represent 25% of the cases, of which 40% to 50% have obstructive forms of hypertrophic cardiomyopathy.

Occasionally, LVH can be present in neonates and children. In infants, it is associated with heart failure and high mortality rates. Differential diagnosis should include neuromuscular and metabolic syndromes, which can simulate HCM, such as Friedrich’s ataxia, mitochondrial myopathies, incomplete expressions of Noonan and LEOPARD syndromes, and infants born to diabetic mothers. In families affected by the disease, it is possible to identify children between 4 and 12 years of age with thickened left ventricular (LV) walls. These may or may not correspond to malignant forms, with greater potential for disease progression and early tendency to sudden death.

HCM phenotypic penetrance is usually high, but it is age- and gene-dependent. The development of HCM may be observed in adults harboring the mutant gene, between the ages of 30 and 60. The presence of symptoms and LV outflow tract obstruction is not frequent among these individuals. The prognostic significance of these conditions remains unclear, despite a marked susceptibility to sudden death and progression to heart failure.

The diagnosis of HCM should be suspected in the presence of symptoms, heart murmurs and ECG abnormalities, or even by family screening. At least 50% of the cases are familial. Diagnostic criteria for familial and nonfamilial HCM in its clinical phase overlap. The absence of family history does not rule out a genetic etiology. It is a disease of incomplete phenotypic penetrance, and de novo mutations can be transmitted to offspring. Minimal changes in electrocardiogram and imaging modalities are adopted as criteria for preclinical diagnosis of adults with familial HCM (table 2).

Most patients are mildly symptomatic or completely asymptomatic. Others have severe limitation and progress to heart failure or die prematurely. Sudden death is reported in 50% to 70% of the patients, especially adolescents and adults younger than 35 years of age, although it may occur at any age. The annual incidence of HCM is approximately 1% in adults and 4% in children. Cellular disarray and reparative fibrosis, together with LV outflow tract obstruction, microcirculatory disease, and physical exercise, produce electrophysiological instability and favor the genesis of fatal arrhythmias, either as a primary disorder or secondary to myocardial ischemia. In young people and in cardiac troponin T gene mutations, with greater predisposition to premature sudden death, cell disarray and myocardial ischemia are regarded as determinants in the development of fatal arrhythmias. In other gene mutations, the degree of fibrosis is related to nonsustained ventricular tachycardia, being an important arrhythmogenic substrate.

Electrocardiogram

The electrocardiogram is abnormal in 75% to 95% of the patients. These changes are seen early, even before adolescence, when Doppler echocardiogram is usually normal. In adult-onset hypertrophic cardiomyopathy, ECG abnormalities may precede the appearance of LV hypertrophy. The following are considered major electrocardiographic diagnostic criteria: left ventricular overload, deep Q-waves > 40 ms intraventricular conduction disturbances, T-wave inversion, minor VR changes, deep S-waves in V2.

Table 2 - Preclinical diagnosis of hypertrophic cardiomyopathy: changes in adults with familial forms

<table>
<thead>
<tr>
<th>Method</th>
<th>Abnormality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrocardiogram</td>
<td>LV hypertrophy overload, deep Q-waves</td>
</tr>
<tr>
<td></td>
<td>&gt; 40 ms intraventricular conduction disturbances</td>
</tr>
<tr>
<td></td>
<td>T-wave inversion, minor VR changes, deep S-waves</td>
</tr>
<tr>
<td></td>
<td>in V2</td>
</tr>
<tr>
<td>Doppler echocardiogram</td>
<td>LV wall thickness = 12 mm in the anterior septum</td>
</tr>
<tr>
<td></td>
<td>or posterior wall and/or 14 mm in the posterior</td>
</tr>
<tr>
<td></td>
<td>septum or free wall associated to moderate SAM</td>
</tr>
<tr>
<td></td>
<td>or redundant leaflets.</td>
</tr>
<tr>
<td>Tissue Doppler Strain/strain rate</td>
<td>Decreased LV systolic and early diastolic</td>
</tr>
<tr>
<td></td>
<td>velocities</td>
</tr>
<tr>
<td></td>
<td>Decreased LV strain</td>
</tr>
<tr>
<td>Magnetic resonance</td>
<td>Structural segmental abnormalities of the</td>
</tr>
<tr>
<td></td>
<td>myocardium and LV, focal fibrosis in</td>
</tr>
<tr>
<td></td>
<td>areas with segmental hypertropy</td>
</tr>
<tr>
<td>Molecular genetic diagnosis</td>
<td>Disease-causing gene mutations</td>
</tr>
</tbody>
</table>

SVE - left ventricular overload, VR - ventricular repolarization, LV - left ventricle, SAM - systolic anterior motion of the mitral valve.

Diagnosis of hypertrophic cardiomyopathy: changes in adults with familial forms

Electrocardiogram

- LV hypertrophy overload, deep Q-waves
- > 40 ms intraventricular conduction disturbances
- T-wave inversion, minor VR changes, deep S-waves in V2

Doppler echocardiogram

- LV wall thickness = 12 mm in the anterior septum or posterior wall and/or 14 mm in the posterior septum or free wall associated to moderate SAM or redundant leaflets.

Tissue Doppler Strain/strain rate

- Decreased LV systolic and early diastolic velocities
- Decreased LV strain

Magnetic resonance

- Structural segmental abnormalities of the myocardium and LV, focal fibrosis in areas with segmental hypertrophy

Molecular genetic diagnosis

- Disease-causing gene mutations
such as interventricular conduction disturbances, minor changes in ventricular repolarization, and deep S-waves in lead V2, may occasionally occur in the absence of heart disease8.

Holter ECG monitoring shows rhythm disturbances in 90% of the adults affected by the disease2. Ventricular extrasystoles and nonsustained ventricular tachycardia are found in 20% to 30% of the patients23,24. Bradyarrhythmias, supraventricular tachycardias, and atrial fibrillation may precede the development of ventricular tachycardia2. Repetitive, prolonged episodes of nonsustained ventricular tachycardia predispose to ventricular fibrillation, particularly in patients younger than 302. Ventricular arrhythmias are rarely seen in children, adolescents and young adults, but when present they have a higher positive predictive value for sudden death26. Sustained ventricular tachycardia may indicate association with LV apical aneurysms or ischemic heart disease1.

Doppler echocardiogram

Doppler echocardiogram plays a decisive role in the diagnosis of HCM, since it identifies major structural and functional changes typical of the disease, as well as a wide phenotypic diversity. Left ventricular hypertrophy ranges from mild to severe, and from localized to diffuse. No morphological pattern of LVH is regarded as truly typical, although asymmetric forms with predominant involvement of the interventricular septum and diffuse hypertrophy are the most frequent4. Concentric forms represent 1% to 5% of the cases27,28. Less typically, hypertrophy can be confined to a single ventricular segment, such as the posterior portion of the septum or the anterolateral and posterior free walls, or even LV apical regions27.

The extent and pattern of LVH are inversely correlated with age, and are not associated with gender and functional class14. Adolescents and young adults often have extreme hypertrophy, with LV wall thickness ≥ 30 mm, which predisposes to sudden death29. Measurements ranging from 15 to 30 mm are common, revealing different degrees of myocardial involvement14. Borderline thicknesses ≤ 15 mm denote an incipient process and should be differentiated from physiological states, such as athlete’s heart14.

Any value for LV wall thickness may be identified in the presence of a mutant gene, even those regarded as normal16. Consequently, screening of families affected by HCM based on LV maximal wall thickness is obviously limited, particularly during childhood and preadolescence. In a recent study, an echocardiographic score calculated as the sum of wall thicknesses obtained in four different LV segments has been shown to be more accurate, especially among younger people23. Left ventricular wall thicknesses of 12 mm in the anterior septum or posterior wall or 14 mm in the posterior septum or free wall are regarded as criterion for the preclinical diagnosis of adult familial forms, when associated with moderate mitral valve systolic anterior motion (SAM) or redundant valve leaflets8.

There is a potential relationship between the degree of LVH and the responsible gene. Mutations in the gene encoding the β-myosin heavy chain are associated with diffuse, severe disease35. In troponin T mutations, hypertrophy is usually mild or absent10. Hypertrophic cardiomyopathy caused by myosin-binding protein C gene mutations is associated with normal LV wall thickness at a younger age11.

Doppler echocardiogram allows a distinction to be made between obstructive and non-obstructive forms of HCM. Obstruction affects more often LV outflow tract, due to the anterior or posterior mitral valve leaflet making contact with the basal portions of the interventricular septum13,14. Mitral valve deformities may contribute to a subaortic gradient. In 45% of the cases of obstructive HCM, the anterior mitral leaflet is elongated or has an anomalous insertion directly into the papillary muscle31. The systolic anterior motion (SAM) of the mitral valve, partly attributed to the Venturi effect, may lead to valvular regurgitation, with the regurgitant jet directed posteriorly14. Less frequently, there is mid-ventricular obstruction due to excessive papillary muscle hypertrophy and malalignment27.

The degree of obstruction, assessed by continuous Doppler, is dynamic, changing in response to several stimuli and in serial measurements. The gradient changes spontaneously in a same individual, being influenced by intravascular volume, contractility, and afterload2,32. Provocative maneuvers lack standardization and include Valsalva, amyl nitrite inhalation, postextrasystole potentiation, dobutamine infusion, and exercise2,28. A recent study, in which patients without subaortic obstruction under rest conditions were assessed by exercise Doppler echocardiography, has shown predominance of obstructive HCM, corresponding to 70% of the patients33. The presence of LV outflow tract obstruction is regarded as an independent predictor of progression to heart failure. The likelihood of death from HCM, heart failure, or stroke is higher in these cases32. While LV outflow tract obstruction was associated with elevated risk of sudden death34, its role as a predisposing factor is not well established yet32.

Conventional assessment of global LV systolic function, based on estimated ejection fraction, shows normal or elevated values3,28. It does not exclude contractile dysfunction, which is better documented by tissue Doppler and strain/strain rate imaging. Left ventricular enlargement with decreased ejection fraction and wall thinning occurs in 5% to 10% of patients who reach maturity13,35. Assessment of diastolic filling using transmural Doppler shows abnormal LV relaxation, even though restrictive or pseudonormal filling patterns are also found1.

Tissue Doppler

Tissue Doppler echocardiography is more sensitive than standard Doppler echocardiography for detecting minor changes in left ventricular function19,36. In patients with overt hypertrophic cardiomyopathy, it can detect left ventricular functional impairment with systolic velocities (S) lower than that obtained in normal controls31. Long-axis diastolic dysfunction is observed by delayed and reduced early (E’) and late (A’) velocities, as well as prolonged regional deceleration and isovolumic relaxation times35.

The E’/E ratio, which can reflect increased LV filling pressure, predicts the degree of exercise tolerance19. There is a correlation between septal E’, functional class, and plasma levels of B-type natriuretic peptide (BNP)40.
Tissue Doppler imaging permits the detection of changes indicative of left intraventricular asynchrony. Prolonged intraventricular systolic delay indicates predisposition to ventricular tachycardia.

Tissue Doppler may be useful in the differential diagnosis between hypertrophic cardiomyopathy and athlete’s heart. Heterogeneous and reduced systolic and diastolic velocities with asynchrony of contraction are not seen in physiologic states, in which LF function is normal or supernormal.

This method also enables identification of preclinical HCM. Systolic (Sa) and early diastolic (Ea) velocities measured by tissue Doppler were reported to be lower in mutation carriers without LVH than in age-matched normal controls. The subsequent development of LVH in serial echocardiography demonstrates that tissue Doppler is effective in identifying genetically affected patients who are more likely to express the HCM phenotype. Despite the promising results obtained so far, only systematic studies involving a larger number of families may define the true role of tissue Doppler as a predictor of LVH development. Just as the disease may not manifest itself later in life because of the incomplete penetrance, minor changes in left ventricular function may not be detected by tissue Doppler.

**Strain and strain rate**

More sensitive echocardiographic techniques for characterizing LV structure and function include measurement of the extent and rate of segmental myocardial deformation using strain and strain rate imaging. Midseptal longitudinal strain is decreased in HMC patients, the same being true for the basal portions of the septum and mid-lateral wall, compared with normal controls. Two-dimensional strain analysis shows a decrease in all strain components: longitudinal, radial, circumferential, and transverse.

Strain/strain rate measurement may be useful in the diagnosis of left ventricular dysfunction both in HCM individuals and mutation carriers (phenotype-negative). Larger studies are needed to assess its effectiveness in detecting HCM at a preclinical stage.

**Magnetic resonance imaging**

Magnetic resonance imaging (MRI) provides information on LV morphology and function, including ventricular mass and volumes, in addition to global and regional diastolic and systolic function. Flow dynamics in the LV outflow tract and the degree of mitral regurgitation can also be determined. It also shows the extent and distribution of myocardial hypertrophy, especially when it is limited to a single LV segment. This imaging modality is clearly superior to Doppler echocardiography for diagnosing LV apical hypertrophy, as well as hypertrophy localized in the anterolateral LV free wall, for which ultrasound has shown less diagnostic accuracy.

In patients with massive LVH, magnetic resonance offers higher resolution than Doppler echocardiography in assessing maximal wall thickness. Despite its undeniable role in the identification of phenotypic variants of HCM, it does not replace Doppler echocardiography in the morphological assessment of all patients with HCM.

Magnetic resonance may establish the differential diagnosis with athlete’s heart by determining the geometric index, which is calculated as maximal LV end-diastolic wall thickness to LV end-diastolic volume index ratio. It can also differentiate between concentric hypertrophy cardiomyopathy and infiltrative myocardial diseases, such as amyloidosis, characterized by an increase in interatrial septal thickness, as well as in right atrial and right ventricular free wall thickness.

Left ventricular segmental function is assessed by measurement of systolic wall thickening and circumferential strain. Reduced circumferential shortening associated with an abnormal strain pattern is found in hypertrophied segments.

Left ventricular diastolic function measured by contrast-enhanced magnetic resonance may be used to assess HCM, but warrants additional studies.

The histopathological substrate of the disease can be analyzed by gadolinium-enhanced MRI. Late enhancement is found in 80% of the patients, involving 0 to 48% of myocardial mass with different patterns of distribution.

It is directly related to areas of reparative fibrosis, in which collagen is the predominant component. Two patterns of distribution are described: diffuse and confluent. Late enhancement has prognostic value in HCM. Its extent is associated with greater predisposition to sudden death and progressive left ventricular dilation. The diffuse pattern, more than the confluent, is associated with the presence of at least two risk factors for sudden death. When multifocal, it is correlated with a greater degree of fibrosis and decreased ejection fraction.

Areas of late enhancement were not detected in mutation carriers without the HCM phenotype, suggesting that fibrosis only develops after appearance of LV hypertrophy. In 81% of the phenotype-negative subjects, MRI revealed the presence of triangular, deep, bright structural abnormalities in the basal and mid segments of the LV inferoseptal wall. The depth of these images decreased with increased wall thickness, which may explain the absence of such a description in histopathological studies, usually restricted to forms with complete phenotypic expression. Gadolinium-enhanced MRI may facilitate the differential diagnosis with Fabry disease, which accounts for 4% of patients diagnosed with HCM.

Phosphorus-31 nuclear magnetic resonance spectroscopy may be potentially used in the preclinical diagnosis of HCM. The cardiac phosphocreatine-to-ATP ratio, which can reflect abnormalities in myocardial metabolism, is 30% lower in HCM patients, even in the absence of LVH, despite the overlapping results with the normal control group.

**Endomyocardial biopsy**

Endomyocardial biopsy is performed to identify the histopathological substrate of the disease, the less specific feature and focal distribution of which limit its use in routine screening for HCM. More recently, studies based on necropsy or in explanted hearts have analyzed the interrelation between several histopathological components and their respective association with clinical outcomes.
Endomyocardial biopsy, using light microscopy, shows various degrees of cellular hypertrophy and fibrosis. On electron microscopy, morphological changes are usually nonspecific. Cellular disarray, lying deep within the interventricular septum, is often beyond the reach of the biotome, occupying approximately 30% of the left ventricular wall. It is not pathognomonic, affecting, in a localized form, subjects with normal hearts or with congenital heart diseases. Its extension is inversely related to age. Cellular disarray is not associated with specific LVH patterns, but is more diffuse in the presence of maximal wall thickness ≤ 20 mm, preserved systolic function, and young patients with sudden premature death.

Interstitial or reparative fibrosis may be focal or occupy extensive areas of the myocardium, and it is directly related to age, maximal LV wall thickness, and the presence of a dilated chamber. Fibrosis is more severe in patients who progress to sudden death at a more advanced age.

Microcirculation impairment is characterized by wall thickening due to myointimal hyperplasia and the ensuing luminal narrowing of small intramural arteries, being more pronounced in the interventricular septum. It is implicated in the development of reparative fibrosis and progression to dilated hypertrophic cardiomyopathy. This is an early finding that affects even the very young.

Endomyocardial biopsy may be used for the differential diagnosis with LVH of other etiologies, interventricular septal tumors, and infiltrative diseases, such as cardiac amyloidosis. Myocardial infiltrative processes may be clinically indistinguishable from HCM, such as Pompe disease, which affects children. In Fabry disease, an X-linked recessive lysosomal disorder, potentially treatable, deficiency of α-galactosidase A is associated with glycosphingolipid deposition in the myocardium in older men. Mutations in genes related to cell metabolism, described recently, mimic familiar hypertrophic cardiomyopathy. Mutations in the gene encoding the β-subunit of the AMP-activated protein kinase (PRKAG2) cause storage disease, in which Wolff-Parkinson-White syndrome and premature conduction disease are associated with varying degrees of pseudo ventricular hypertrophy. Mutations in the lysosome-associated membrane protein-2 (LAMP2) result in Danon disease, with massive myocardial hypertrophy accompanied by Wolff-Parkinson-White syndrome. In both diseases, histopathological examination reveals lack of cellular disarray and presence of glycogen-containing vacuoles.

Electrophysiological studies

The role of electrophysiological studies (EPS) using programmed ventricular stimulation to assess the arrhythmogenic substrate of HCM has not yet been established. Although some relationship has been demonstrated between inducibility and prognosis, its predictive accuracy is debatable. It may be helpful in patients with unexplained syncope. High resolution ECG has low predictive accuracy as well. T-wave alternans is regarded as predictive of ventricular arrhythmias and sudden death. Its contribution to risk stratification in HCM may be limited and needs further evaluation.

Molecular genetic diagnosis

DNA analysis is the most definitive method for identifying HCM in its clinical and preclinical phases. The heterogeneous molecular substrate, represented by hundreds of mutations in multiple genes, adds complexity to the genetic diagnosis and limits its use in routine clinical practice. Because of the marked allelic heterogeneity, together with low individual prevalence of mutations, it is difficult to assess the genotype-phenotype relationship. The significant inter- and intrafamilial phenotypic variability is attributed to the action of modifying agents, either environmental or genetic, and to the likelihood of occurring more than one mutation in one or more genes.

Molecular genetic diagnosis is a valuable tool for assessing familial forms of the disease, particularly those associated with sudden death or late clinical expression. It enables the early release of normal family members and follow-up of those who carry mutations but have no evidence of the disease. Prospective studies are needed to determine whether these individuals will necessarily express the phenotype. Preclinical diagnosis may produce adverse psychological effects, particularly in children and adolescents. In this regard, multidisciplinary genetic counseling is considered mandatory.

Molecular genetic diagnosis helps differentiate other forms of LVH and phenocopies, including metabolic storage diseases, which are clinically indistinguishable from HCM.

The use of genetic analysis in risk stratification for sudden death is supported by descriptions of malignant mutations. Early studies based on large pedigrees relate certain phenotypes to the mutant genes and discriminate between mutations with good and poor prognosis. More recent studies provided new data on HCM clinical and genetic profile, revealing less specific phenotypes and lower prevalence of malignant mutations. For the purpose of prognostic evaluation, it is necessary to expand the analysis of genotype-phenotype relationships, including larger, unrelated families with a higher number of affected members.

As molecular genetic diagnosis is expensive and time-consuming, it has been limited to research centers. Single-strand conformation polymorphisms (SSCP) analysis can map 60% to 80% of the cases. The advent of automated, direct DNA sequencing contributes to its use on a clinical scale, since it allows rapid screening for up to eight sarcomeric genes, but is still expensive. The likelihood of false-negatives due to mutations in genes that were not assessed does exist.

Molecular genetic diagnosis should prompt implementation of measures designed to prevent or delay disease progression, such as gene therapy. The multitude of structural and functional disorders involving contractile proteins has been a drawback to the development of effective therapeutic strategies.

Conclusion

Hypertrophic cardiomyopathy is a disease with a heterogeneous molecular genetic substrate and significant phenotypic variability, which makes clinical and preclinical diagnosis very complex. Higher resolution imaging modalities and affordable molecular techniques will allow early diagnosis...
and implementation of measures that may prevent the development of LVH and progression to sudden death.

Potential Conflict of Interest
No potential conflict of interest relevant to this article was reported.

References


